Executive Briefing Series (formerly The Food & Drug Letter)
Oct. 7, 2005
Clinical Trial Databases Provide Risks, Benefits, GSK Exec Says
Drugmakers can reduce their liability risks and avoid other pitfalls associated with establishing clinical trial databases by using a review team to ensure the trial results are complete and free of promotional claims, says a GlaxoSmithKline (GSK) executive.
This article is viewable by subscribers only. To view this article, please select an option below.